 |
| 13-May-13 | Reiterated |
Stifel |
Buy |
$42 → $36 |
|
| 08-May-13 | Reiterated |
RBC Capital Mkts |
Underperform |
$28 → $29 |
|
| 17-Apr-13 | Reiterated |
Stifel |
Buy |
$38 → $42 |
|
| 10-Apr-13 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| 31-Jan-13 | Reiterated |
Cantor Fitzgerald |
Hold |
$26 → $34 |
|
| 31-Jan-13 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 04-Jan-13 | Reiterated |
UBS |
Buy |
$42 → $40 |
|
| 04-Jan-13 | Reiterated |
Stifel Nicolaus |
Buy |
$40 → $38 |
|
| 04-Jan-13 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$29 → $25 |
|
| 17-Dec-12 | Reiterated |
Cantor Fitzgerald |
Hold |
$28 → $26 |
|
| 14-Dec-12 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$33 → $29 |
|
| 14-Dec-12 | Downgrade |
Needham |
Hold → Underperform |
|
|
| 06-Nov-12 | Reiterated |
Cantor Fitzgerald |
Hold |
$31 → $28 |
|
| 05-Oct-12 | Downgrade |
RBC Capital Mkts |
Outperform → Sector Perform |
$36 → $35 |
|
| 01-Oct-12 | Reiterated |
Cantor Fitzgerald |
Hold |
$37 → $31 |
|
| 30-May-12 | Reiterated |
Stifel Nicolaus |
Buy |
$53 → $50 |
|
| 30-May-12 | Reiterated |
Cantor Fitzgerald |
Hold |
$39 → $37 |
|
| 02-May-12 | Downgrade |
Cantor Fitzgerald |
Buy → Hold |
$39 |
|
| 06-Jan-12 | Initiated |
William Blair |
Outperform |
|
|
| 10-Jun-11 | Upgrade |
Standpoint Research |
Hold → Buy |
$55 |
|
|
|
| 23-May-13 09:41AM | ENDO HEALTH SOLUTIONS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Stateme EDGAR Online |
| 22-May-13 05:45PM | Merck Enters into Strategic Deal Zacks |
| 20-May-13 09:30AM | FDA Painkiller Abuse Concerns Creating Opportunity For Pfizer at Seeking Alpha |
| 09:12AM | An Undervalued Play in Pharma at Motley Fool |
| 16-May-13 02:04PM | Analysts: Bristol-Myers Shares Will Give Back Gains and 3 More Research Notes to Check Out at Wall St. Cheat Sheet |
| 01:31PM | Innovative Therapeutic Development for Duchenne Muscular Dystrophy Moves Niche Stocks Up 300% to 400%: An Expert Portfolio Manager Discusses Investing in Health Care Wall Street Transcript |
| 12:38PM | Last Week's 13D/G Filings By Leading Fund Managers In Healthcare And Technology at Seeking Alpha |
| 10:00AM | Endo Health Solutions Inc Stock Hold Recommendation Reiterated (ENDP) at TheStreet |
| 14-May-13 01:04PM | ENDO HEALTH SOLUTIONS INC. Financials EDGAR Online Financials |
| 12:24PM | Blue Ridge Capital betting big on a pharma stock at MarketWatch |
| 13-May-13 05:40PM | Setback for Endo Health on Opana ER Zacks |
| 03:07PM | Stocks Weaken In Late Trade; Qihoo, YY Slide at Investor's Business Daily |
| 02:58PM | Analysts: Cisco Valuation is Positive and 3 Other Research Notes to Read at Wall St. Cheat Sheet |
| 11:33AM | Analyst Moves: ENDP, PRU, AZO at Forbes |
| 11:04AM | Endo Health Stock Falls On Unusually High Volume (ENDP) at TheStreet |
| 10:31AM | What Companies Will This FDA Decision Impact? at Wall St. Cheat Sheet |
| 09:25AM | On The Fly: Pre-market Movers at theflyonthewall.com |
| 09:17AM | Stocks to Watch: Theravance, Endo Health, Perion Network at The Wall Street Journal |
| 07:32AM | Endo Health downgraded to Sell from Neutral at Lazard Capital theflyonthewall.com |
| 11-May-13 06:43PM | These 4 Stocks Saw Trading Price Swings This Past Week Post Earnings at Wall St. Cheat Sheet |
| 10-May-13 06:21PM | FDA Rejects Endo Petition To Protect Its Opana Painkiller at Forbes -5.28% |
| 06:14PM | FDA allows generic forms of Endo Health's Opana ER painkiller at Reuters |
| 05:53PM | FDA denies request to block generic painkiller AP |
| 05:25PM | BRIEF-Endo Health down 2.8 percent in extended trade at Reuters |
| 05:00PM | InPlay: Endo Health responds to FDA's denial of OPANA ER citizen peititon; generics could reduce adjusted diluted EPS by ~$0.55 in 2013 (stock halted) Briefing.com |
| 04:56PM | Endo Health Solutions Responds to FDA's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone PR Newswire |
| 04:25PM | Endo Loses Bid to Stop Sales of Generic Painkiller Rivals at Bloomberg |
| 03:40PM | InPlay: Endo Health halted with news pending Briefing.com |
| 03:00PM | [video] 3 to Watch: ENDP, SSYS, TTWO at CNBC |
| 09-May-13 10:47AM | Can Warner Chilcott Start Growing Again? at Motley Fool |
| 08-May-13 05:55PM | Earnings Beat at Endo Health, Sales Slip Zacks |
| 05:01PM | Endo Health Solutions Inc (ENDP): Today's Featured Health Care Laggard at TheStreet |
| 09:36AM | Company News for May 8, 2013 Zacks |
| 07-May-13 09:08PM | Endo Health Solutions Increases Sales but Misses Revenue Estimate at Motley Fool |
| 12:30PM | Endo Health Solutions Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 11:27AM | Santarus Stock Lifts Off On Q1 Earnings, Guidance at Investor's Business Daily |
| 09:49AM | Endo Pharmaceuticals Holdings Earnings: Heres Why Investors are Ambivalent Now at Wall St. Cheat Sheet |
| 08:46AM | Endo Health turns 1Q profit, affirms 2013 forecast AP |
| 08:30AM | Endo Health Solutions Inc. Earnings Call scheduled for 8:30 am ET today CCBN |
| 07:14AM | InPlay: Endo Health beats by $0.02, misses on revs; reaffirms FY13 EPS in-line, reaffirms revs in-line Briefing.com |
| 07:07AM | Q1 2013 Endo Health Solutions Inc. Earnings Release - Before Market Open CCBN |
| 07:00AM | Endo Reports First Quarter Financial Results PR Newswire |
| 01:17AM | ENDO HEALTH SOLUTIONS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online |
| 06-May-13 07:13PM | Endo Pharmaceuticals Holdings Earnings: Your Sneak Peek to the Big Announcement at Wall St. Cheat Sheet |
| 04:55PM | First Head-to-Head Study Shows GreenLight XPS® Laser Therapy Equally Safe And Effective With Faster Recovery As Commonly Used TURP For Treatment Of BPH CNW Group |
| 04:07PM | InPlay: Endo Health: First head-to-head study shows GreenLight XPS laser therapy equally safe and effective with faster recovery as commonly used TURP for treatment of BPH Briefing.com |
| 04:02PM | First Head-to-Head Study Shows GreenLight XPS® Laser Therapy Equally Safe And Effective With Faster Recovery As Commonly Used TURP For Treatment Of BPH PR Newswire |
| 10:00AM | Endo Health Solutions Inc Stock Hold Recommendation Reiterated (ENDP) at TheStreet |
| 07:24AM | Drug companies attempt to make painkillers that can't be abused, WSJ reports theflyonthewall.com |
| 05-May-13 10:08PM | [$$] The Painkiller Holy Grail at The Wall Street Journal |
| 03-May-13 09:58AM | Endo Health Reaches New 52-Week High (ENDP) at TheStreet |
| 02-May-13 11:08AM | David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co., Interviews with The Wall Street Transcript: Alternative Dosage Forms Create Barriers Against Competition in Generics Wall Street Transcript |
| 01-May-13 12:43PM | Weak Quarter At Auxilium Overshadows Execution On Long-Term Strategy at Seeking Alpha |
| 29-Apr-13 04:56PM | UPDATE 2-Auxilium cuts sales outlook, expands urology business at Reuters |
| 26-Apr-13 11:48AM | Ramin Najafi, Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY), Interviews with The Wall Street Transcript Wall Street Transcript |
| 25-Apr-13 10:03AM | This ETF Holds Stocks Insiders Want to Own at Forbes |
| 23-Apr-13 10:00AM | Endo Health Solutions Inc Stock Hold Recommendation Reiterated (ENDP) at TheStreet |
| 20-Apr-13 12:30PM | This Week in Biotech: Part 1 at Motley Fool |
| 19-Apr-13 12:34PM | Endo Health Stock Hits New 52-Week High (ENDP) at TheStreet |
| 18-Apr-13 05:27PM | UPDATE 1-US panel divided over safety of Endo's testosterone drug at Reuters |
| 04:47PM | FDA panel split on safety of testosterone drug AP |
| 03:38PM | U.S. FDA panel deadlocked over Endo's testosterone drug at Reuters |
| 12:01AM | ArcelorMittal, Bayer, OxyContin: Intellectual Property at Bloomberg |
| 17-Apr-13 04:32PM | On The Fly: Closing Wrap at theflyonthewall.com |
| 03:54PM | Endo Health Rises On Unusually High Volume (ENDP) at TheStreet |
| 03:01PM | 4 Stocks Rising on Unusual Volume at TheStreet |
| 02:04PM | Cirrus Logic is a Buy and 3 More Analyst Opinions to Read at Wall St. Cheat Sheet |
| 01:17PM | Acura Pharma rises on FDA OxyContin decision AP |
| 12:08PM | FDA Bars Old OxyContin Generics: Read-Through To Continue Boosting Endo at Seeking Alpha |
| 12:07PM | Analysts: Heres a Chance to Buy Netflix and 3 Other Analyst Notes To Check Out at Wall St. Cheat Sheet |
| 10:13AM | Endo, Acura gain after FDA blocks OxyContin generics at theflyonthewall.com |
| 07:31AM | Coloplast Falls Amid Vaginal Mesh Lawsuits: Copenhagen Mover at Bloomberg |
| 16-Apr-13 06:55PM | On The Fly: After Hours Movers at theflyonthewall.com |
| 06:39PM | Shell and Valero Lose Power and 3 Other Hot Stocks at Wall St. Cheat Sheet |
| 04:55PM | FDA Bans Generics of Purdue's Older OxyContin Painkiller at Bloomberg |
| 12:48PM | Shell and Valero Lose Power and 3 Other Hot Stocks at Wall St. Cheat Sheet |
| 09:44AM | UPDATE 1-FDA staff concerned about safety of Endo's testosterone injection at Reuters |
| 08:43AM | FDA staff concerned about safety of Endo's testosterone injection at Reuters |
| 15-Apr-13 04:00PM | Endo to Announce First Quarter 2013 Financial Results on May 7, 2013 PR Newswire |
| 11:30AM | 3 Can't-Miss FDA Actions This Week at Motley Fool |
| 10-Apr-13 05:01PM | Today's Drugs Industry Featured Laggard: Endo Health Solutions Inc (ENDP) at TheStreet |
| 01:56PM | Tackling Cancer: Bladder Cancer's Biggest Current & Upcoming Players at Motley Fool |
| 01:33PM | Endo Pharmaceuticals Gets a Thumbs Down and 4 More Analyst Downgrades to Know at Wall St. Cheat Sheet |
| 02:56AM | Endo Health downgraded by Standpoint Research Briefing.com |
| 08-Apr-13 07:40AM | Last Week's Best- And Worst-Performing Medical Stocks at Forbes |
| 05-Apr-13 04:50AM | Acadia Pharmaceuticals Implies Sanuwave Could Triple On New Study Design at Seeking Alpha |
| 03-Apr-13 05:09PM | VIX - Options Volatility And Market Sonar: Wednesday Recap at Seeking Alpha |
| 04:14PM | Endo Health Rises On Unusually High Volume (ENDP) at TheStreet |
| 08:02AM | Endo Health's New Exec Expected To Swing Right Into Action at Seeking Alpha |
| 31-Mar-13 03:42AM | Endo Health's New CEO To Reveal Strategy: Good News For Investors? at Seeking Alpha |
| 28-Mar-13 11:10PM | ENDO HEALTH SOLUTIONS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan EDGAR Online |
| 11:19AM | Endo Health's New CEO Will Be Revealing His Strategy - Good News For Investors? at Seeking Alpha |
| 26-Mar-13 01:02AM | Don't Get Too Worked Up Over Endo Health Solutions's Latest Numbers at Motley Fool |
| 25-Mar-13 04:37AM | Surgery Restoring Penis After Prostate Cancer Increasing at Bloomberg |
| 24-Mar-13 09:00AM | Surgery Restoring Penis After Prostate Cancer Increasing at Bloomberg |
| 18-Mar-13 12:02PM | Which Medical Device Companies Have the Most Upside Potential in 2013? An Expert Equity Analyst Discusses Renal Denervation and Transcatheter Heart Valves, as well as the European Slowdown Wall Street Transcript |
| 15-Mar-13 05:23PM | Endo Health Solutions Larger Than S&P 500 Component J.C. Penney at Forbes |
| 14-Mar-13 10:29AM | 11.5% of XPH Holdings Seeing Recent Insider Buys at Forbes |
| 08-Mar-13 04:45PM | ENDO HEALTH SOLUTIONS INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 07-Mar-13 01:04PM | ENDO HEALTH SOLUTIONS INC. Financials EDGAR Online Financials |
|
|
| Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company's Endo Pharmaceuticals segment offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel for pain, urology, endocrinology, and oncology. Its Qualitest segment provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and hypertension markets. The company's AMS segment offers various technology solutions comprising AMS 700 MS series, AMS 800 artificial urinary sphincter, GreenLight XPS laser system, Elevate transvaginal pelvic floor repair system, and Monarc subfascial hammock products in the areas of men's and women's health, and BPH therapy. Its HealthTronics segment provides urological services, such as lithotripsy, prostate treatment, anatomical pathology, and electronic medical record services to urologists, hospitals, surgery centers, and clinics; and manufactures, sells, and maintains medical devices for tissue and tumor ablation. The company's products under development primarily include Aveed, an injectable testosterone preparation to treat male hypogonadism; BEMA Buprenorphine, a transmucosal form of buprenorphine in Phase III trials for treating moderate to severe chronic pain; ODM-201, an androgen receptor antagonist in Phase II clinical testing to treat castrate resistant prostate cancer; and EN3342, a polyurethane implant in Phase I/II trials for the maintenance treatment of schizophrenia in adults. It serves pharmacy chains directly; and hospitals, governmental agencies, pharmacies, and physicians through wholesale drug distributors. The company was formerly known as Endo Pharmaceuticals Holdings Inc. and changed its name to Endo Health Solutions Inc. in May 2012. Endo Health Solutions Inc. was founded in 1997 and is headquartered in Malvern, Pennsylvania. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Gergel Ivan P. | EVP, R&D and CSO | Apr 24 | Option Exercise | 20.74 | 105,190 | 2,181,471 | 94,241 | Apr 26 04:02 PM | | Gergel Ivan P. | EVP, R&D and CSO | Apr 24 | Sale | 36.45 | 138,225 | 5,038,911 | 0 | Apr 26 04:02 PM | | MANOGUE CAROLINE B | Exec. V.P., CLO & Secy | Apr 09 | Option Exercise | 15.24 | 35,000 | 533,400 | 97,014 | Apr 11 04:41 PM | | MANOGUE CAROLINE B | Exec. V.P., CLO & Secy | Apr 09 | Sale | 35.00 | 35,000 | 1,225,000 | 62,014 | Apr 11 04:41 PM | | NASH DAVID | Director | Mar 05 | Buy | 30.80 | 670 | 20,636 | 10,411 | Mar 06 07:02 PM | | Rudio Daniel | Vice President, Controller | Feb 28 | Sale | 30.91 | 520 | 16,073 | 526 | Mar 01 04:55 PM | | Rudio Daniel | Vice President, Controller | Feb 27 | Sale | 29.88 | 770 | 23,008 | 526 | Mar 01 04:55 PM | | Rudio Daniel | Vice President, Controller | Feb 21 | Sale | 28.10 | 482 | 13,544 | 526 | Feb 25 05:33 PM | | HYATT MICHAEL | Director | Jan 18 | Option Exercise | 11.05 | 5,000 | 55,250 | 262,346 | Jan 23 06:16 PM | | MANOGUE CAROLINE B | Exec. V.P., CLO & Secy | Dec 31 | Option Exercise | 0.00 | 19,513 | 0 | 50,348 | Jan 03 09:30 PM | | Gergel Ivan P. | EVP, Research & Development | Dec 31 | Option Exercise | 0.00 | 33,271 | 0 | 33,271 | Jan 03 09:29 PM | | LEVIN ALAN G | EVP, Chief Financial Officer | Dec 31 | Option Exercise | 0.00 | 32,023 | 0 | 50,154 | Jan 03 09:27 PM | | Holveck David | President & CEO | Dec 31 | Option Exercise | 0.00 | 89,155 | 0 | 144,227 | Jan 03 09:25 PM | | LEVIN ALAN G | EVP, Chief Financial Officer | Nov 15 | Option Exercise | 20.09 | 9,954 | 199,976 | 18,131 | Nov 19 05:04 PM | | Holveck David | President & CEO | Nov 12 | Buy | 26.84 | 7,425 | 199,287 | 31,497 | Nov 14 05:29 PM | | Rudio Daniel | Vice President, Controller | Aug 10 | Sale | 32.23 | 1,957 | 63,074 | 292 | Aug 14 05:59 PM | | LEVIN ALAN G | EVP, Chief Financial Officer | Jun 15 | Buy | 29.68 | 3,200 | 94,976 | 3,200 | Jun 19 05:00 PM | | Holveck David | President & CEO | Jun 12 | Buy | 29.23 | 8,550 | 249,917 | 24,072 | Jun 14 05:02 PM |
|
|
|
|
|
|
